Literature summary for 1.5.1.3 extracted from

Xu, X.; Gammon, M.D.; Wetmur, J.G.; Rao, M.; Gaudet, M.M.; Teitelbaum, S.L.; Britton, J.A.; Neugut, A.I.; Santella, R.M.; Chen, J.
A functional 19-base pair deletion polymorphism of dihydrofolate reductase (DHFR) and risk of breast cancer in multivitamin users (2007), Am. J. Clin. Nutr., 85, 1098-1102.

Search for more literature for 1.5.1.3

Application

Application	Comment	Organism
medicine	a 19-bp deletion polymorphism is not associated with overall breast cancer risk, although a borderline significant additive interaction between the dihydrofolate reductase genotype and multivitamin use is observed. Multivitamin supplements may place a subgroup of women, i.e., those with the19-bp allele, at elevated risk of developing breast cancer. A dose-dependent relation between dihydrolfolated reductase expression and the 19 bp deletion genotype is observed	Homo sapiens

Protein Variants

Protein Variants	Comment	Organism
additional information	19-base pair deletion polymorphism is not associated with overall breast cancer risk	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)